Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 88

Sort by

Sort Order Select

Journal Articles

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Blood (2021) 138 (22): 2278–2289.

https://doi.org/10.1182/blood.2021012021

Published: 2021

Includes: Supplemental data

Journal Articles

Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Javier Pinilla Ibarz, Meixiao Long, John Lister, Jennifer A. Woyach, Friedrich Graf Finckenstein, Madan Jagasia, Selda Samakoglu, Bhagyashree Yadav, Huiling Li, John C. Byrd

Blood (2021) 138 (Supplement 1): 3846.

https://doi.org/10.1182/blood-2021-145775

Published: 2021

Journal Articles

Machine Learning Reveals Patient Phenotypes and Stratifies Outcomes in Chronic Graft-Versus-Host Disease

Ashley Y Wu, Sierra Barone, Jocelyn Gandelman, Madan Jagasia, Jonathan Michael Irish

Blood (2021) 138 (Supplement 1): 2951.

https://doi.org/10.1182/blood-2021-147472

Published: 2021

Journal Articles

Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Mukta Arora, MD, Madan Jagasia, MBBS, MS, MMHC, Antonio Di Stasi, MD, Michael L Meyers, MD PhD, Christine Quaranto, Aaron Schmitt, Serap Sankoh, Mohammad Issam Abu Zaid, MBBS, Geoff R Hill, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, Peter Ordentlich, PhD, Stephanie J. Lee, MDMPH

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-141553

Published: 2020

Journal Articles

Cytomegalovirus Promotes Aberrant Memory CD4 T Cell Differentiation and Immune Function after Allogeneic Stem Cell Transplantation

Albert Yeh, MD, Madan Jagasia, MBBS, MS, MMHC, Kimberly Dahlman, PhD, Jonathan Michael Irish, PhD, Anupama Reddy, PhD, Sierra Barone, BS, Kate Chilson, MA, Lynn E. Onstad, ScM, Ping Zhang, MD PhD, Tae Kon Kim, MD PhD, Stephanie J. Lee, MDMPH, Geoff R Hill, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-134829

Published: 2020

Journal Articles

Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)

Corey Cutler, MD MPH, FRCPC, Stephanie J. Lee, MDMPH, Sally Arai, MD MS, Marcello Rotta, MD, Behyar Zoghi, MD, Aravind Ramakrishnan, MD, David Eiznhamer, PhD, Olivier Schueller, PhD, Zhongming Yang, PhD, Laurie S. Green, MD, Sanjay K. Aggarwal, MD, Bruce R. Blazar, MD, Steven Z. Pavletic, MD MS, Madan Jagasia, MBBS, MS, MMHC

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-139445

Published: 2020

Journal Articles

Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness

Mohamad Mohty, Ernst Holler, Madan Jagasia, Robert Jenq, Florent Malard, Paul Martin, Gérard Socié, Robert Zeiser

Blood (2020) 136 (17): 1903–1906.

https://doi.org/10.1182/blood.2020007336

Published: 2020

Journal Articles

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Madan Jagasia, Miguel-Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah, Yi-Bin Chen, Salman Fazal, Fitzroy W. Dawkins, Michael C. Arbushites, Chuan Tian, Laura Connelly-Smith, Michael D. Howell, H. Jean Khoury

Blood (2020) 135 (20): 1739–1749.

https://doi.org/10.1182/blood.2020004823

Published: 2020

Includes: Supplemental data

Journal Articles

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

Blood (2020) 135 (2): 97–107.

https://doi.org/10.1182/blood.2019003125

Published: 2020

Includes: Supplemental data

Journal Articles

Diagnostic Potential of Five Different Biomechanical Parameters to Detect Sclerotic Cutaneous Graft-Versus-Host Disease

Fuyao Chen, BS, Laura Wang, BS, Yvette Ssempijja, BS, Arved Vain, PhD, Madan Jagasia, MBBS, MS, MMHC, Eric R. Tkaczyk, MD PhD

Blood (2019) 134 (Supplement_1): 2002.

https://doi.org/10.1182/blood-2019-129381

Published: 2019

Journal Articles

Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantation Research (CIBMTR) and the Pediatric Health Information System (PHIS)

Caitlin W Elgarten, MD MSc, Yimei Li, PhD, Yuan-Shung V. Huang, MS, Richard Aplenc, MD PhD, Michael T. Hemmer, MS, Mukta Arora, MD, Stephen R. Spellman, MS, Tao Wang, PhD, Madan Jagasia, MBBS, MS, MMHC, Margaret L. MacMillan, MD, Joseph Pidala, MD, Brian T. Fisher, DO, MSCE, Matt Hall, PhD

Blood (2019) 134 (Supplement_1): 599.

https://doi.org/10.1182/blood-2019-130466

Published: 2019

Journal Articles

Interobserver Reproducibility of the Myoton and Durometer Devices to Measure Skin Stiffness and Hardness in Chronic Cutaneous Graft-Versus-Host Disease Patients

Fuyao Chen, BS, Laura Wang, BS, Arved Vain, PhD, Yvette Ssempijja, BS, Laura Dellalana, BS, Kathy Zhang, Alexis Hood, BS, Heidi Chen, PhD, Madan Jagasia, MBBS, MS, MMHC, Eric R. Tkaczyk, MD PhD

Blood (2019) 134 (Supplement_1): 4515.

https://doi.org/10.1182/blood-2019-129125

Published: 2019

Journal Articles

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Blood (2019) 134 (Supplement_1): 4516.

https://doi.org/10.1182/blood-2019-127325

Published: 2019

Journal Articles

Noninvasive Microscopic Imaging Reveals Increased Leukocyte Adhesion and Rolling in Skin of Acute Graft-Versus-Host Disease Patients Compared to Post-Transplant Controls

Inga Saknite, PhD, Michael T Byrne, DO, Madan Jagasia, MBBS, MS, MMHC, Eric R. Tkaczyk, MD PhD

Blood (2019) 134 (Supplement_1): 4533.

https://doi.org/10.1182/blood-2019-123795

Published: 2019

Journal Articles

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia

Michael T Byrne, DO, Nathalie Danielson, MSN, Adrianne Rasche, MSN, Rachel Hammers, MSN, Kathryn A Culos, PharmD, Katie S Gatwood, PharmD, Houston Wyatt, PharmD, Kristin Fogo, BSN, Bhagirathbhai Dholaria, MBBS, Brian G Engelhardt, MD, Paul Brent Ferrell, Jr., MD, Madan Jagasia, MBBS, MS, MMHC, Adetola A. Kassim, MDMS, Sanjay R Mohan, MD MSCI, Bipin N. Savani, MD, Stephen A. Strickland, MD, Salyka M. Sengsayadeth, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2643.

https://doi.org/10.1182/blood-2019-129146

Published: 2019

Journal Articles

Key Histopathology Features of Cutaneous Acute Graft-Versus-Host Disease Can be Detected Noninvasively

Inga Saknite, PhD, Melissa Gill, MD, Alessi-Fox Christi, MS, Jeffrey P Zwerner, MD PhD, Julia S Lehman, MD, Michi M Shinohara, MD, Roberto A Novoa, MD, Michael T Byrne, DO, Madan Jagasia, MBBS, MS, MMHC, Salvador Gonzalez, MD PhD, Marco Ardigo, MD PhD, Eric R. Tkaczyk, MD PhD

Blood (2019) 134 (Supplement_1): 3278.

https://doi.org/10.1182/blood-2019-131317

Published: 2019

Journal Articles

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)

Madan Jagasia, MBBS, MS, MMHC, Amandeep Salhotra, MD, Carlos R. Bachier, MD, Behyar Zoghi, MD, PhD, FACP, Aleksandr Lazaryan, MDPhDMPH, Daniel J. Weisdorf, MD, James Essell, MD, Laurie S. Green, MD, Olivier Schueller, PhD, Lindy Huang, Zhongming Yang, PhD, David Eiznhamer, PhD, Sanjay K. Aggarwal, MD, Bruce R. Blazar, MD, Stephanie J. Lee, MD MPH

Blood (2019) 134 (Supplement_1): 872.

https://doi.org/10.1182/blood-2019-125986

Published: 2019

Journal Articles

KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) — Pharmacodynamics and Updated Results

Madan Jagasia, MD MS, Amandeep Salhotra, MD, Carlos R. Bachier, MD, James Essell, MD, Daniel J. Weisdorf, MD, Behyar Zoghi, MD PhD, Laurie S. Green, MD, Olivier Schueller, PhD, Alexandra Zanin-Zhorov, PhD, Jonathan M. Weiss, PhD, David Eiznhamer, PhD, Sanjay K. Aggarwal, Bruce R. Blazar, MD, Stephanie J. Lee, MD MPH

Blood (2018) 132 (Supplement 1): 602.

https://doi.org/10.1182/blood-2018-99-111896

Published: 2018

Journal Articles

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Madan Jagasia, MD MS, Miguel-Angel Perales, MD, Mark A Schroeder, MD, Haris Ali, MD, Nirav N Shah, MD, Yi-Bin Chen, MD, Michael C. Arbushites, Fitzroy Dawkins, MD, Chuan Tian, PhD, Hanna Jean Khoury, MD FACP

Blood (2018) 132 (Supplement 1): 601.

https://doi.org/10.1182/blood-2018-99-116342

Published: 2018

Journal Articles

Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy

Robert Frank Cornell, MD, Samuel Z. Goldhaber, MD, Brian G Engelhardt, MD, Javid Moslehi, MD, Madan Jagasia, MD MS, Daryl Patton, Shelton Lacy Harrell, MSN, Robert L Hall, MSN, Houston Wyatt, PharmD, Gregory Piazza, MD

Blood (2018) 132 (Supplement 1): 1233.

https://doi.org/10.1182/blood-2018-99-112577

Published: 2018

NARROW

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Machine Learning Reveals Patient Phenotypes and Stratifies Outcomes in Chronic Graft-Versus-Host Disease

Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Cytomegalovirus Promotes Aberrant Memory CD4 T Cell Differentiation and Immune Function after Allogeneic Stem Cell Transplantation

Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)

Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

Diagnostic Potential of Five Different Biomechanical Parameters to Detect Sclerotic Cutaneous Graft-Versus-Host Disease

Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantation Research (CIBMTR) and the Pediatric Health Information System (PHIS)

Interobserver Reproducibility of the Myoton and Durometer Devices to Measure Skin Stiffness and Hardness in Chronic Cutaneous Graft-Versus-Host Disease Patients

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Noninvasive Microscopic Imaging Reveals Increased Leukocyte Adhesion and Rolling in Skin of Acute Graft-Versus-Host Disease Patients Compared to Post-Transplant Controls

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia

Key Histopathology Features of Cutaneous Acute Graft-Versus-Host Disease Can be Detected Noninvasively

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)

KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) — Pharmacodynamics and Updated Results

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only